ANNAPOLIS, Md., May 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc.
(Amex: PIP) a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that its financial results
for the first quarter of 2008 will be released on Tuesday, May 13, 2008.
PharmAthene management will be hosting a conference call to discuss its
first quarter 2008 financial results. The call is scheduled to begin at
4:30 p.m. Eastern Time on Tuesday, May 13, 2008 and will last approximately
45 minutes.
The dial-in number within the United States is 866-770-7129. The
dial-in number for international callers is 617-213-8067. The participant
passcode is 26177716.
A replay of the conference call will be available for 30 days,
beginning at approximately 6:30 p.m. Eastern Time on May 13, 2008 until
approximately 11:50 p.m. Eastern Time June 13, 2008. The dial-in number
from within the United States is 888-286-8010. For international callers,
the dial-in number is 617-801-6888. The participant passcode is 15975144.
The conference call will also be webcast and can be accessed from the
company's website at http://www.pharmathene.com. A link to the webcast may be
found on both the Home Page and also under the Investor Relations section
of the website. The webcast will be available for 30 days, or until
approximately June 13, 2008.
About PharmAthene, Inc.
PharmAthene (Amex: PIP) was formed in March 2001 with a mission to
become the premier company worldwide specializing in the development and
commercialization of therapeutic and prophylactic products for defense
against biological and chemical threats. Since its inception, PharmAthene
has pursued an acquisitive growth strategy focused on high priority, next
generation biodefense products that the government has expressed a clear
need and intent to procure. PharmAthene's portfolio currently includes five
potential best- in-class biodefense medical countermeasures: Recombinant
Protective Antigen (rPA) anthrax vaccine; Valortim(TM), an anthrax
anti-toxin therapeutic which is being co-developed with Medarex;
Protexia(R) a novel recombinant bioscavenger to prevent and treat
organophosphorous nerve agent poisoning; RypVax(TM), a recombinant dual
antigen plague vaccine; and finally, third generation rPA anthrax vaccine
technology. For more information on PharmAthene, please visit
http://www.PharmAthene.com.
SOURCE PharmAthene, Inc.
 back to top
Related links:
http://www.pharmathene.com/
CONTACT:
Stacey Jurchison of PharmAthene, Inc.,
+1-410-269-2610, JurchisonS@PharmAthene.com
|
